Market Cap 227.59M
Revenue (ttm) 53.40M
Net Income (ttm) 2.93M
EPS (ttm) N/A
PE Ratio 40.43
Forward PE 40.43
Profit Margin 5.49%
Debt to Equity Ratio 0.00
Volume 705,600
Avg Vol 1,305,988
Day's Range N/A - N/A
Shares Out 80.42M
Stochastic %K 59%
Beta -0.26
Analysts Strong Sell
Price Target $11.00

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 696 9345
Address:
2 University Plaza, Suite 100, Hackensack, United States
MauriceMauriceMaurice
MauriceMauriceMaurice Mar. 15 at 12:17 PM
0 · Reply
Merlintrader
Merlintrader Mar. 15 at 11:14 AM
$PLX https://www.merlintrader.com/biotech-trading-without-the-fairy-tales-risks-catalysts-and-reality/
0 · Reply
jcon777
jcon777 Mar. 15 at 4:35 AM
$PLX About three days til earnings. Maybe this will finally be the beginning of good things that keep getting better and better. I'm looking forward to hearing what will the relationship with Secarna do for PLX.
0 · Reply
PLX_BULLS
PLX_BULLS Mar. 15 at 2:08 AM
$PLX ugh
1 · Reply
CliffordCapital
CliffordCapital Mar. 14 at 6:47 PM
$PLX $PLX – Simple long-term model based only on Elfabrio royalties Assumptions: • Global Fabry market grows to ~$4B by 2030 • Elfabrio reaches ~25% market share • Protalix receives ~25% royalty/economic share from Chiesi sales • ~80M shares outstanding • Conservative valuation multiple: 3× revenue Projected Protalix revenue from Elfabrio: 2026: ~$101M 2027: ~$135M 2028: ~$173M 2029: ~$207M 2030: ~$250M Applying a 3× revenue multiple gives the following potential valuation path: 2026: $303M market cap → **$3.79/share** 2027: $405M market cap → **$5.06/share** 2028: $519M market cap → **$6.49/share** 2029: $621M market cap → **$7.76/share** 2030: $750M market cap → **$9.38/share** Important: This model only includes Elfabrio royalties. It does not include Elelyso revenue, pipeline value, milestones, or other potential upside. Just a simple framework for thinking about long-term valuation. Do your own research.
2 · Reply
pmcd777
pmcd777 Mar. 14 at 6:41 PM
$PLX this is an interesting thread. too long to screenshot and share so if you have FB, you should be able to access it if you'd like to. Since it's public, may not need facebook but not sure. https://www.facebook.com/groups/540104499396202/?multi_permalinks=9468150656591497
1 · Reply
pmcd777
pmcd777 Mar. 14 at 6:33 PM
$PLX I can't recall for sure but this guy seems familiar. Maybe he's a Chiesi Elfabrio ambassador.
0 · Reply
pmcd777
pmcd777 Mar. 14 at 6:25 PM
$PLX decided to add the second image this way instead
1 · Reply
pmcd777
pmcd777 Mar. 14 at 6:24 PM
$PLX First, second and third attempt to post failed :( so trying again with just one image. I'll try to add the second image as a comment. Maybe this will work. Poking around on FB a bit and found this. Poster started on fabrazyme and complained that insurance company was pushing elfabrio, but doesn't look like the switch was ever made for cost purposes. However, poster developed ADAs with fabrazyme so did ultimately switch to Elfabrio! Located in US so no nearterm hopes of E4W dosing. Have to wonder how observations by doctors of patients like this that are switched to elfabrio because of ADAs influences their prescribing elfabrio from the get go. More likely as time continues to pass, it seems.
0 · Reply
sentinelles
sentinelles Mar. 14 at 5:39 AM
$PLX biotechnology company Protalix BioTherapeutics
1 · Reply
Latest News on PLX
Protalix BioTherapeutics Letter to Stockholders

Jan 5, 2026, 6:50 AM EST - 2 months ago

Protalix BioTherapeutics Letter to Stockholders


Why Is Protalix BioTherapeutics Stock Falling On Friday?

Oct 17, 2025, 11:23 AM EDT - 5 months ago

Why Is Protalix BioTherapeutics Stock Falling On Friday?


Protalix BioTherapeutics to Present at Investor Summit Virtual

Sep 11, 2025, 10:55 AM EDT - 6 months ago

Protalix BioTherapeutics to Present at Investor Summit Virtual


Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Dec 23, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders


Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Dec 26, 2023, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics Issues 2024 Letter to Stockholders


MauriceMauriceMaurice
MauriceMauriceMaurice Mar. 15 at 12:17 PM
0 · Reply
Merlintrader
Merlintrader Mar. 15 at 11:14 AM
$PLX https://www.merlintrader.com/biotech-trading-without-the-fairy-tales-risks-catalysts-and-reality/
0 · Reply
jcon777
jcon777 Mar. 15 at 4:35 AM
$PLX About three days til earnings. Maybe this will finally be the beginning of good things that keep getting better and better. I'm looking forward to hearing what will the relationship with Secarna do for PLX.
0 · Reply
PLX_BULLS
PLX_BULLS Mar. 15 at 2:08 AM
$PLX ugh
1 · Reply
CliffordCapital
CliffordCapital Mar. 14 at 6:47 PM
$PLX $PLX – Simple long-term model based only on Elfabrio royalties Assumptions: • Global Fabry market grows to ~$4B by 2030 • Elfabrio reaches ~25% market share • Protalix receives ~25% royalty/economic share from Chiesi sales • ~80M shares outstanding • Conservative valuation multiple: 3× revenue Projected Protalix revenue from Elfabrio: 2026: ~$101M 2027: ~$135M 2028: ~$173M 2029: ~$207M 2030: ~$250M Applying a 3× revenue multiple gives the following potential valuation path: 2026: $303M market cap → **$3.79/share** 2027: $405M market cap → **$5.06/share** 2028: $519M market cap → **$6.49/share** 2029: $621M market cap → **$7.76/share** 2030: $750M market cap → **$9.38/share** Important: This model only includes Elfabrio royalties. It does not include Elelyso revenue, pipeline value, milestones, or other potential upside. Just a simple framework for thinking about long-term valuation. Do your own research.
2 · Reply
pmcd777
pmcd777 Mar. 14 at 6:41 PM
$PLX this is an interesting thread. too long to screenshot and share so if you have FB, you should be able to access it if you'd like to. Since it's public, may not need facebook but not sure. https://www.facebook.com/groups/540104499396202/?multi_permalinks=9468150656591497
1 · Reply
pmcd777
pmcd777 Mar. 14 at 6:33 PM
$PLX I can't recall for sure but this guy seems familiar. Maybe he's a Chiesi Elfabrio ambassador.
0 · Reply
pmcd777
pmcd777 Mar. 14 at 6:25 PM
$PLX decided to add the second image this way instead
1 · Reply
pmcd777
pmcd777 Mar. 14 at 6:24 PM
$PLX First, second and third attempt to post failed :( so trying again with just one image. I'll try to add the second image as a comment. Maybe this will work. Poking around on FB a bit and found this. Poster started on fabrazyme and complained that insurance company was pushing elfabrio, but doesn't look like the switch was ever made for cost purposes. However, poster developed ADAs with fabrazyme so did ultimately switch to Elfabrio! Located in US so no nearterm hopes of E4W dosing. Have to wonder how observations by doctors of patients like this that are switched to elfabrio because of ADAs influences their prescribing elfabrio from the get go. More likely as time continues to pass, it seems.
0 · Reply
sentinelles
sentinelles Mar. 14 at 5:39 AM
$PLX biotechnology company Protalix BioTherapeutics
1 · Reply
Psykido
Psykido Mar. 14 at 3:23 AM
$PLX Looks like the EU approval was already partially priced in around March 9. Do you guys think management will actually share patient numbers on the earnings call, or will they just talk about potential EU market share? Also wondering if there’s any wildcard that could move the stock big after earnings. What do you guys think? 🤔📈
0 · Reply
jcon777
jcon777 Mar. 14 at 1:56 AM
$PLX regarding Protalix new partner, Secarna, they specialize in oligonucleotide therapy. A quick Google search found this about oligonucleotide therapy, and i wonder if this partnership will be lucrative for PLX in some way or another: "How much does oligonucleotide therapy cost? Nusinersen, an antisense oligonucleotide, is given by intrathecal injection, at a cost of US$125 000 per injection. Six doses are required in the first year and three doses per year after that; hence, the treatment amounts to US$750 000 for the first year and US$375 000 for every year afterwards"
1 · Reply
DragonAlgo
DragonAlgo Mar. 13 at 9:48 PM
🐉 $PLX CALL — DragonAlgo® Signal Contract: PLX CALL Expiry: 2026-05-15 | Strike: $2.50 | Type: CALL Option Plan (premium): Entry: $0.57 Stop: $0.41 TP1: $0.75 TP2: $0.98 TP3: $1.38 🔗 https://dragonalgo.com
0 · Reply
Artfldgr
Artfldgr Mar. 13 at 7:20 PM
1 · Reply
TheMotleyMonk
TheMotleyMonk Mar. 13 at 6:39 PM
$PLX Hot off the wires from Simply Wall Street: https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/d1w0zxn7-ema-reviews-and-rare-disease-trends-will-open-global-markets-whhq/updates/9-9-analysts-have-reiterated-an-dollar1100-price-target-for-protalix
0 · Reply
brunoq14
brunoq14 Mar. 13 at 2:14 PM
$PLX Things could certainly be worse. A new Fabry dosing schedule considered favorable to Protalix is now available, following a turnaround of an initially negative CHMP Opinion. A $25M regulatory milestone payment will give the company a welcome financial boost. Even if Q4 is not spectacular, the company is in pretty good shape.
1 · Reply
Zkoko_Bio
Zkoko_Bio Mar. 13 at 2:09 PM
$PLX is this the little pre-earnings run-up? I'm out on Tuesday and back on Wednesday after ER call @ $1.60 maybe $1.50 Pragmatism....
1 · Reply
Artfldgr
Artfldgr Mar. 13 at 10:29 AM
$PLX don't fck with ROTC!!
1 · Reply
PureLand
PureLand Mar. 13 at 10:02 AM
$PLX Wow, they’re adjusting all the numbers ahead of today’s $50 buyout announcement! 🙄
1 · Reply
m2882
m2882 Mar. 13 at 4:31 AM
$PLX I hate this stock
4 · Reply
arnolddunn
arnolddunn Mar. 12 at 9:53 PM
$PLX range bound going on 4 yrs….1-3…zzzzzz.
1 · Reply
pmcd777
pmcd777 Mar. 12 at 8:31 PM
$PLX It could be worse. We could be invested here in a declining market AND also be on shaky financial ground. Happily, that's not the case and soon we'll see news of receipt of that $25M milestone reinforcing that very thing. Not to say this doesn't suck that we are at these levels. It absolutely does. Really painful that someone could come in and scoop up thousands and thousands of shares with the current setup and have a lower cost basis than I do who has been languishing here for years. SMH. Sometimes it's hard to believe that PLX will pay off big, like many other bios have/do, given its track record. It def should but one thing is for sure, nothing is worth more than someone is willing to pay for it, no matter what the owner/holder thinks their possession is worth. Hopefully our diamond in the perpetual rough will one day shine. Time will tell. We will see. GLTA of us!
0 · Reply